Rationale and Dose Regimen for Sitagliptin/ Glimepiride Combination Therapy in Type 2 Diabetes Treatment
Keywords:monotherapies, synergistic, insulin, GLP-1.
This study explores how glimepiride, alone or in combination with sitagliptin, affected glycemic control in
Type 2 diabetes patients. Type 2 diabetes was induced in rats by feeding them a high-fat diet and injecting
them with Alloxan and nicotinamide. Forty-two rats were divided equally into seven groups. Negative
control and group 2-7: rats fed with the HFD Positive control (diabetic non-treated) Group (T1, T2, T3, T4
and T5) were treated with monotherapy and combination. All the treatment regimen reduces fasting blood
glucose and enhanced GLP-1 and insulin level as indicated by an increase in the area under the curve.
Additionally, as opposed to monotherapies, the combination category had better glycemic regulation. As a
result, we assume that sitagliptin/glimepiride combined therapy has a synergistic effect.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Re use and mixing of content policy- We follow Creative Commons Licence Policy. We follow CC BY. Please refer below for all details
This license lets others distribute, remix, adapt, and build upon our work, even commercially, as long as they credit us for the original creation.
- The journal allows readers to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose.
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to retain publishing rights without restrictions